首页> 外文期刊>Cellular and molecular biology >MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R
【24h】

MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R

机译:MiR-30a通过靶向IGF1R通过AKT信号通路抑制非小细胞肺癌的进展

获取原文
获取原文并翻译 | 示例
           

摘要

MicroRNAs play critical roles in the development and progression of human cancers. Although miR-30a has been suggested to function as a tumor repressor in several tumors, its role in non-small cell lung cancer (NSCLC) has not been investigated in detail. This study investigated the expression and role of miR-30a in human NSCLC. The expression of miR-30a is significantly decreased in clinical NSCLC tissues and cell lines. Overexpression of miR-30a inhibited NSCLC cell proliferation, G1/S and S/G2 transition in vitro, whereas suppression of miR-30a facilitated NSCLC cell proliferation, G1/S and S/G2 transition. Using a luciferase reporter assay, insulin-like growth factor 1 receptor (IGF1R) was determined to be a direct target of miR-30a. Furthermore, silencing IGF1R resulted in the same biologic effects of miR-30a overexpression in NSCLC cells, which included suppressed NSCLC cell proliferation and trigering cell cycle arrest through PI3K/AKT signaling pathway by inhibiting cell cycle regulators (CDK2, CDK4, Cyclin A2, Cyclin D1). These results demonstrate that miR-30a influences NSCLC progression through PI3K/AKT signaling pathway by targeting IGF1R in A549 cells, which suggest miR-30a as a novel strategy for NSCLC diagnosis and treatment.
机译:MicroRNA在人类癌症的发生和发展中起关键作用。尽管已经提出miR-30a在几种肿瘤中起抑癌作用,但尚未详细研究其在非小细胞肺癌(NSCLC)中的作用。这项研究调查了miR-30a在人NSCLC中的表达和作用。在临床NSCLC组织和细胞系中,miR-30a的表达明显降低。 miR-30a的过表达在体外抑制NSCLC细胞增殖,G1 / S和S / G2转变,而抑制miR-30a则促进NSCLC细胞增殖,G1 / S和S / G2转变。使用荧光素酶报告基因测定,胰岛素样生长因子1受体(IGF1R)被确定为miR-30a的直接靶标。此外,沉默IGF1R导致miR-30a过表达在NSCLC细胞中具有相同的生物学效应,包括抑制NSCLC细胞增殖,并通过抑制细胞周期调节因子(CDK2,CDK4,Cyclin A2,Cyclin A,通过PI3K / AKT信号通路触发细胞周期阻滞D1)。这些结果表明,miR-30a通过靶向A549细胞中的IGF1R,通过PI3K / AKT信号通路影响NSCLC进展,这表明miR-30a是NSCLC诊断和治疗的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号